Beta Drugs Ltd. · NSE:BETA
Beta Drugs — Investor Presentation (May 2021)
21 slides from Beta Drugs's investor presentation, May 5, 2021
Slide 1: Beta Drugs Ltd Corporate Presentation
B E TA D R U G S LT D C O R P O R AT E P R E S E N TAT I O N
Slide 2: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 3: Our Genesis
Our Genesis The Journey of Beta Drugs Limited (Adley Group) began early 80’s with the ardent efforts of Late Shri Vijay Batra. He was a visionary and businessman par excellence. He had foreseen the scope in niche segment like Oncology and laid the foundation of Indian Pharma Multinational in Oncolog
Slide 4: Our Milestones
Our Milestones Laid the foundation of Adley group by Late Shri Vijay Batra Entered into the Oncology market Set up 1st Oncology unit in Adley formulations Pvt Ltd. Foray into the international market Set up a new “state of art” manufacturing facility for Oncology formulations- Beta Drugs Limited Dev
Slide 5: Who we are: Mission, Vision, Values
Who we are Our Mission To touch the lives of million of cancer patients by expanding access of quality & affordable drugs through cutting edge You build Hope… technology & advanced R&D We accelerate it Our Vision Because Every moment of life is previous for To achieve a sustainable leadership in com
Slide 6: Our Strength: Formulations and API Plant
Our Strength Formulations and API Plant
Slide 7: Our Market Reach
Our Market Reach DOMESTIC MARKET Beta drugs Limited has leadership position in Indian market with 88 SKUs. Products are available in major corporate & Govt hospitals
Slide 8: Our Product Portfolio
Liles Db ADSUNIB @apieaP BEXINIB — CAPAD ADOXI — ADPLATIN Sib Cpls 125255055 Araaide Cpt ng «AMO TEDES SME Capecone Ties 300mg eee Z08N3Ing Cult ng Adlante Gem-RTU AMGICIN — ADGEF ERLOTAD TEMOZAD ‘Lenwatinib Capsules 4/10 Mg. ee 4g Gemcitabine Inj 200/1000mg, Gefitinib Tablets 250mg, Erlotnib Tablet
Slide 9: Leading position in Oncology: Domestic Market
Domestic Market Finished Formulation Sales Domestic Formulation Sales (Cr) Leading position in Oncology 2 Brands occupy No 1 position in India 6 Novel Molecules launched in FY 20-21 New Molecules to be launched in 6 FY 21-22 1st One to launch Protein Shot 20 28 33 FY 18-19 FY 19-20 FY 20-21 Exclusiv
Slide 10: Current Position in Own Brand Sales
1st To Launch Molecules in India Domestic Market Current Position in Own Brand Sales Beedan Adsunib Oncology division overview • Currently operating with 56 Molecules & 88 SKUs • Sales and Marketing of product is supported by 36 Sales representatives and strategically located logistics network of ov
Slide 11: Our Global Reach
Our Global Reach We are now globally represented by our subsidiaries or sales partners in over 15 Countries: Uzbekistan, Nigeria, Kenya, Uganda, Sri Lanka, Nepal, Myanmar, Yemen, Honduras, Venezuela, Tanzania, Ethiopia, Philippines, Malaysia & Ivory coast. BDL is ready to file PICS by June this year
Slide 12: Our Expertise-Regulatory
Our Expertise-Regulatory Our regulatory department works on the guidelines of CTD and ICH. Our team is engaged in day to day development of dossiers - DMFs, interacting with all the manufacturing sites to keep updating them for regular regulatory developments and features in the international arena.
Slide 13: Our Strength- Strong In-house API development
Our Strength- Strong In-house API development VERTICAL INTEGRATION API STRENGTH COMPANY’S FOCUS AND DETAILS: • Complex Multi-Step Synthesis & Scale Up • To launch APIs in the cytotoxic segment • Containment& High Potency APIs • To be the first few players in the entry of new TKI’s • Scale up of prod
Slide 14: Our Strength- Strong In-house API development
Our Strength- Strong In-house API development
Slide 15: Our Strength: Strong Research & Development (R&D)
Our Strength: Strong Research & Development (R&D) Strong R&D capabilities demonstrated by its complex oncology formulations & oncology APIs 5 2 2 2 1 1 Beta Drugs limited is amongst a handful of Indian Oncology companies to foresee the importance of R&D and invest heavily in these activities. 1 2 2
Slide 16: Our Indian Partners
Our Indian Partners BDL is acknowledged as a high quality manufacturing company by many leading pharmaceutical companies in India. BDL has impressive clientele base of more than 49 Indian companies.
Slide 17: Financial Performance
Financial Performance TRACK RECORD OF CONSISTENT GROWTH AND VALUE CREATION EBITDA REVENUE 30 120 25.24 25 100 18.32 116.61 20 80 AMOUNT IN CRORES 90.81 AMOUNT IN CRORES 15 12.18 60 9.7 65.93 50.57 10 40 5 20 0 0 FY2018 FY2019 FY2020 FY2021 FY2018 FY2019 FY2020 FY2021
Slide 18: Financial Performance: Key Ratios
Financial Performance Key Ratios ROE ROCE 20% 22% 16% 17% 21% 19% 2019 2020 2021 2019 2020 2021 CURRENT RATIO 1.99 1.53 1.33 2019 2020 2021
Slide 19: Financial Performance: Profitability Ratios
Financial Performance Profitability Ratios GROSS MARGIN EBITDA MARGIN 22% 20% 40% 18% 37% 38% 2019 2020 2021 2019 2020 2021 OPERATING/EBIT 16% 16% 14% 2019 2020 2021
Slide 20: Financial Performance: Solvency Ratios
Financial Performance Solvency Ratios DEBT RATIO INTEREST COVERAGE RATIO 7.59 0.24 6.52 0.21 5.63 0.14 2019 2020 2021 2019 2020 2021 DEBT TO EQUITY RATIO 0.48 0.39 0.25 2019 2020 2021
Slide 21: Contacts
Innovative product development is a result of our sustained efforts. Contacts Email: sales@betadrugslimited.com Email: info@betadrugslimited.com